Certified Global Research Member

Key Questions Answered

Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the key challenges in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major playersâ€™ financial performance.
Evaluate strategies adopted by major players.
Recommendations

Why Choose Market Research Future?

Vigorous research methodologies for specific market.
Knowledge partners across the globe
Large network of partner consultants.
Ever-increasing/ Escalating data base with quarterly monitoring of various markets
Trusted by fortune 500 companies/startups/ universities/organizations
Large database of 5000+ markets reports.
Effective and prompt pre- and post-sales support.

Schizophrenia Companies

Dedicated to mental health, Schizophrenia companies engage in research and development of innovative therapies and medications. These companies play a vital role in addressing the complexities of schizophrenia, aiming to enhance the lives of affected individuals.

Schizophrenia market

Latest Schizophrenia Companies Updates:

Reviva Pharmaceuticals' brilaroxazine achieved statistically significant improvement in schizophrenia symptoms compared to placebo in a recent Phase 3 trial, potentially offering a new antipsychotic option.

Karuna Therapeutics' KarXT also demonstrated efficacy in its Phase 3 trial, but concerns about hypertension require further investigation.

Focus on novel mechanisms and targets: Companies are exploring drugs targeting the N-methyl-D-aspartate (NMDA) receptor, serotonin systems, and other pathways to address unmet needs in schizophrenia treatment.

Gene editing and personalized medicine approaches: Research is ongoing on utilizing gene editing to potentially treat the underlying causes of schizophrenia, offering long-term solutions.

Bristol Myers Squibb acquires Karuna Therapeutics for $14 billion, highlighting industry interest in novel schizophrenia treatments.

AbbVie enters a new co-development and license agreement with Gedeon Richter to research and develop novel dopamine receptor modulators for neuropsychiatric diseases, including schizophrenia.

List of Schizophrenia Key companies in the market:

Johnson & Johnson

Bristol-Myers Squibb and Company/Otsuka Pharmaceuticals

AstraZeneca

Eli Lilly

Alkermes

Sumitomo Dainippon Pharma

Pfizer

Vanda Pharmaceuticals

Allergan/Geodon Ritcher

Schizophrenia Market Highlights:

Schizophrenia Market Size

Schizophrenia Market Trends

Schizophrenia Market Analysis

Schizophrenia Market Share

Schizophrenia Market Highlights:

Schizophrenia Market Trends

Schizophrenia Market Analysis

Schizophrenia Market Share

Schizophrenia Companies

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

Tailored for You

Dedicated Research on any specifics segment or region.
Focused Research on specific players in the market.
Custom Report based only on your requirements.
Flexibility to add or subtract any chapter in the study.
Historic data from 2014 and forecasts outlook till 2040.
Flexibility of providing data/insights in formats (PDF, PPT, Excel).
Provide cross segmentation in applicable scenario/markets.